|
gptkb:G6PD
|
G6PD activity assay
|
|
gptkb:SM-88
|
Phase II
|
|
gptkb:HER2_receptor
|
immunohistochemistry
|
|
gptkb:NT-0167
|
Phase 1
|
|
gptkb:MRTX849
|
Phase 2
|
|
gptkb:Medigen_COVID-19_vaccine
|
Phase 3
|
|
gptkb:LIBERTY_Robotic_System
|
ongoing (as of 2024)
|
|
gptkb:bryostatin
|
yes
|
|
gptkb:YBB-202
|
Phase 1
|
|
gptkb:DPYD
|
pharmacogenetic testing for 5-FU sensitivity
|
|
gptkb:TAL1
|
RT-PCR for TAL1 expression
|
|
gptkb:KT-474
|
Phase 1
|
|
gptkb:Rogaratinib
|
Phase II/III
|
|
gptkb:Bicycle_Therapeutics
|
gptkb:BT5528
|
|
gptkb:MK2206
|
Phase II
|
|
gptkb:NCT02366143
|
Phase 2
|
|
gptkb:camrelizumab
|
Phase III
|
|
gptkb:NCT03830207
|
Phase 3
|
|
gptkb:WATCHMAN_Left_Atrial_Appendage_Closure_Device
|
gptkb:PROTECT_AF
|
|
gptkb:Von_Willebrand_factor
|
VWF antigen assay
|